# Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease

> **NCT01254773** · PHASE2 · COMPLETED · sponsor: **JANSSEN Alzheimer Immunotherapy Research & Development, LLC** · enrollment: 146 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Experimental Bapineuzumab

## Key facts

- **NCT ID:** NCT01254773
- **Lead sponsor:** JANSSEN Alzheimer Immunotherapy Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-01
- **Final completion:** 2013-03
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2014-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254773, "Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT01254773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*